Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim A Papp

Showing results (81-90 of 219) with videos related to

Pageof 22
Sort By:
Dermatology and Therapy|February 2, 2020
Qualitative Assessment of Adult Patients' Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional StudyBruno Falissard, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of Drugs in Dermatology : JDD|August 27, 2020
Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled StudyKim A Papp, Melinda Gooderham, Michael Droege, et al.
Lancet (London, England)|May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Craig L Leonardi, Alexa B Kimball, Kim A Papp, et al.
Journal of the American Academy of Dermatology|November 19, 2021
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasisAndrew Blauvelt, Tsen-Fang Tsai, Richard G Langley, et al.
International Journal of Dermatology|May 17, 2006
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trialKim A Papp, Reni Bressinck, Scott Fretzin, et al.
Dermatology and Therapy|March 6, 2020
Correction to: Qualitative Assessment of Adult Patients' Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional StudyBruno Falissard, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2021
Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)Kim A Papp, Sascha Gerdes, Craig L Leonardi, et al.
Journal of the American Academy of Dermatology|June 1, 2020
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension studyAndrew Blauvelt, Kim A Papp, Joseph F Merola, et al.
American Journal of Clinical Dermatology|March 31, 2018
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
American Journal of Clinical Dermatology|January 12, 2017
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Pageof 22

Showing results (81-90 of 219) with videos related to

Sort By:
Pageof 22
Dermatology and Therapy|February 2, 2020
Qualitative Assessment of Adult Patients' Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional StudyBruno Falissard, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of Drugs in Dermatology : JDD|August 27, 2020
Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled StudyKim A Papp, Melinda Gooderham, Michael Droege, et al.
Lancet (London, England)|May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Craig L Leonardi, Alexa B Kimball, Kim A Papp, et al.
Journal of the American Academy of Dermatology|November 19, 2021
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasisAndrew Blauvelt, Tsen-Fang Tsai, Richard G Langley, et al.
International Journal of Dermatology|May 17, 2006
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trialKim A Papp, Reni Bressinck, Scott Fretzin, et al.
Dermatology and Therapy|March 6, 2020
Correction to: Qualitative Assessment of Adult Patients' Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional StudyBruno Falissard, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2021
Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)Kim A Papp, Sascha Gerdes, Craig L Leonardi, et al.
Journal of the American Academy of Dermatology|June 1, 2020
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension studyAndrew Blauvelt, Kim A Papp, Joseph F Merola, et al.
American Journal of Clinical Dermatology|March 31, 2018
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
American Journal of Clinical Dermatology|January 12, 2017
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Pageof 22